Evidence map›Paper›PMID 41559247›Full record

ArticleBritish journal of cancer2026

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Benoit Blanchet, Alexandre Xu-Vuillard, Anne Jouinot, Florent Puisset, David Combarel, Olivier Huillard, Félicien Le Louedec, Fabienne Thomas, Marcus Teixeira, Ronan Flippot and 14 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Benoit BlanchetUniversité de Paris, CNRS, INSERM, CiTCoM, U1268, F-75006, Paris, France. benoit.blanchet@aphp.fr.
Alexandre Xu-VuillardDepartment of Medical Oncology, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Georges Pompidou, Paris, France.
Anne JouinotDepartment of Medical Oncology, ARIANE, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
Florent PuissetGroupe de Pharmacologie Clinique Oncologique GPCO-Unicancer, Paris, France.
David CombarelGroupe de Pharmacologie Clinique Oncologique GPCO-Unicancer, Paris, France.
Olivier HuillardDepartment of Medical Oncology, ARIANE, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.ORCID http://orcid.org/0000-0001-9764-0845
Félicien Le LouedecGroupe de Pharmacologie Clinique Oncologique GPCO-Unicancer, Paris, France.
Fabienne ThomasGroupe de Pharmacologie Clinique Oncologique GPCO-Unicancer, Paris, France.
Marcus TeixeiraDepartment of Oncological Medicine, Gustave Roussy, Villejuif, France.
Ronan FlippotDepartment of Oncological Medicine, Gustave Roussy, Villejuif, France.
Loic MoureyOncopole Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059, Toulouse, France.
Laurence AlbigesDepartment of Oncological Medicine, Gustave Roussy, Villejuif, France.
Thomas PudlarzDepartment of Medical Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Saint Antoine, Paris, France.
Charlotte JolyDepartment of Medical Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Henri Mondor, Université de Paris Est, Créteil, France.
Christophe TournigandDepartment of Medical Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Henri Mondor, Université de Paris Est, Créteil, France.
Jonathan ChauvinLixoft, 92160, Antony, France.
Alicja PuszkielBiologie du Médicament - Toxicologie, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
Etienne ChatelutGroupe de Pharmacologie Clinique Oncologique GPCO-Unicancer, Paris, France.
Xavier DeclevesBiologie du Médicament - Toxicologie, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
Michel VidalUniversité de Paris, CNRS, INSERM, CiTCoM, U1268, F-75006, Paris, France.
François GoldwasserDepartment of Medical Oncology, ARIANE, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France.
Stéphane OudardDepartment of Medical Oncology, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Georges Pompidou, Paris, France.
Jacques MedioniDepartment of Medical Oncology, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Georges Pompidou, Paris, France.
Yann-Alexandre VanoDepartment of Medical Oncology, Institut du Cancer Paris CARPEM, Assistance Publique Hôpitaux de Paris, Hôpital Georges Pompidou, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41559247
PMCPMC12859121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.